Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma
- PMID: 20145720
- PMCID: PMC2817389
- DOI: 10.1155/2009/581939
Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma
Abstract
This review will focus on recent knowledge related to circulating autoantibodies (AAbs) to tumor-associated antigens (TAAs) in epithelial ovarian carcinoma. So far, the following TAAs have been identified to elicit circulating AAbs in epithelial ovarian carcinoma: p53, homeobox proteins (HOXA7, HOXB7), heat shock proteins (HSP-27, HSP-90), cathepsin D, cancer-testis antigens (NY-ESO-1/LAGE-1), MUC1, GIPC-1, IL-8, Ep-CAM, and S100A7. Since AAbs to TAAs have been identified in the circulation of patients with early-stage cancer, it has been speculated that the assessment of a panel of AAbs specific for epithelial ovarian carcinoma TAAs might hold great potential as a novel tool for early diagnosis of epithelial ovarian carcinoma.
Similar articles
-
Autoantibodies to tumor-associated antigens in breast carcinoma.J Oncol. 2010;2010:264926. doi: 10.1155/2010/264926. Epub 2010 Nov 21. J Oncol. 2010. PMID: 21113302 Free PMC article.
-
Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma.J Oncol. 2011;2011:982425. doi: 10.1155/2011/982425. Epub 2011 Mar 3. J Oncol. 2011. PMID: 21423545 Free PMC article.
-
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.Cancer Res. 2003 Sep 15;63(18):6076-83. Cancer Res. 2003. PMID: 14522938
-
Autoantibodies against heat shock proteins as biomarkers for the diagnosis and prognosis of cancer.Cancer Biomark. 2017;18(2):105-116. doi: 10.3233/CBM-160117. Cancer Biomark. 2017. PMID: 27983529 Review.
-
Anti-tumor antibodies in ovarian cancer.Am J Reprod Immunol. 2005 Aug;54(2):55-62. doi: 10.1111/j.1600-0897.2005.00287.x. Am J Reprod Immunol. 2005. PMID: 16105096 Review.
Cited by
-
Comparison of candidate serologic markers for type I and type II ovarian cancer.Gynecol Oncol. 2011 Sep;122(3):560-6. doi: 10.1016/j.ygyno.2011.05.039. Epub 2011 Jun 24. Gynecol Oncol. 2011. PMID: 21704359 Free PMC article.
-
Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.Genes Cancer. 2016 Nov;7(11-12):394-413. doi: 10.18632/genesandcancer.126. Genes Cancer. 2016. PMID: 28191285 Free PMC article.
-
Autoantibodies to tumor-associated antigens in breast carcinoma.J Oncol. 2010;2010:264926. doi: 10.1155/2010/264926. Epub 2010 Nov 21. J Oncol. 2010. PMID: 21113302 Free PMC article.
-
Autoantibody signature for the serologic detection of ovarian cancer.J Proteome Res. 2015 Jan 2;14(1):578-86. doi: 10.1021/pr500908n. Epub 2014 Nov 17. J Proteome Res. 2015. PMID: 25365139 Free PMC article.
-
Mining the human autoantibody repertoire: isolation of potent IL17A-neutralizing monoclonal antibodies from a patient with thymoma.MAbs. 2014;6(6):1608-20. doi: 10.4161/mabs.36292. MAbs. 2014. PMID: 25484038 Free PMC article.
References
-
- Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. Journal of Proteome Research. 2008;7(4):1388–1394. - PubMed
-
- Gagnon A, Kim J-H, Schorge JO, et al. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clinical Cancer Research. 2008;14(3):764–771. - PubMed
-
- Koziol JA, Zhang J-Y, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clinical Cancer Research. 2003;9(14):5120–5126. - PubMed
-
- Zhang J-Y, Casiano CA, Peng X-X, Koziol JA, Chan EKL, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiology Biomarkers & Prevention. 2003;12(2):136–143. - PubMed
-
- Scanlan MJ, Welt S, Gordon CM, et al. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Research. 2002;62(14):4041–4047. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous